Last reviewed · How we verify
NCT07516496: MPEDS
Metabolic Phenotyping in vEDS
trial testing No intervention, observational in Vascular Ehlers-Danlos Syndrome in 15 participants. Currently enrolling.
4 March 2030
Quick facts
| Lead sponsor | Cambridge University Hospitals NHS Foundation Trust |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 15 |
| Start date | 5 March 2026 |
| Primary completion | 4 March 2030 |
| Estimated completion | 4 April 2031 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- No intervention, observational
Conditions studied
- Vascular Ehlers-Danlos Syndrome — all drugs for Vascular Ehlers-Danlos Syndrome →
- Vascular Ehlers Danlos Syndrome — all drugs for Vascular Ehlers Danlos Syndrome →
- Vascular EDS (vEDS) — all drugs for Vascular EDS (vEDS) →
Sponsor
Cambridge University Hospitals NHS Foundation Trust
Who can join
Adults 18 to 85, any sex, with Vascular Ehlers-Danlos Syndrome or Vascular Ehlers Danlos Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research study will investigate whether people with vascular Ehlers-Danlos syndrome (vEDS), a rare inherited condition, have problems with the way their body stores and uses fat (adipose tissue). vEDS is caused by changes in a gene called COL3A1, which makes a protein important for the structure of many tissues. While vEDS is best known for making blood vessels fragile, there is some early evidence that it may also affect fat tissue and increase the risk of problems such as insulin resistance (where the body does not respond properly to insulin) and diabetes. Fat tissue is important for keeping the body healthy. It stores extra energy, but it also sends signals to other organs. If fat tissue cannot expand or work properly, fat can build up in the liver or muscles instead, leading to high blood sugar, high cholesterol, and greater risk of diabetes and heart disease. In this study, we will invite 12-17 adults with genetically confirmed vEDS to take part, along with a group of age-, sex-, and weight-matched controls without vEDS. Participants will attend a research visit at Addenbrooke's Hospital, Cambridge. They will have measurements of body fat distribution (using a DEXA scan), a liver scan, blood tests, and a standard oral glucose tolerance test (drinking a sugary drink with blood samples before and after). Some participants may also choose to provide a small fat biopsy under local anaesthetic to allow more detailed analysis of tissue structure. The main aim is to see whether people with vEDS show changes in fat distribution and insulin sensitivity compared to those without vEDS.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07516496
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No intervention, observational
Trials testing the same drug.
- NCT06396520 — Neuroimaging of Babies During Natural Sleep to Assess Typical Development and Cerebral Palsy · recruiting
- NCT05169164 — Latin American Surgical Outcomes Study · completed
- NCT04433871 — COVID-19 in Pediatric Oncology and Hematology Centers in France · unknown
- NCT03326154 — Post-Cholecystectomy Quality of Life · recruiting
- NCT03866291 — ESBL in Patients Returning to Sweden With Traveller's Diarrhoea · completed
Other recruiting trials for Vascular Ehlers-Danlos Syndrome
Currently open trials in the same condition.
- NCT05994664 — Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients · NA · recruiting
- NCT05432466 — Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome · Phase 3 · recruiting
- NCT03440697 — Pathogenetic Basis of Aortopathy and Aortic Valve Disease · active not recruiting
Other Cambridge University Hospitals NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07129577 — Point of Care Testing in Emergency Departments After Mild Traumatic Brain Injury · not yet recruiting
- NCT05093231 — Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer · Phase 2 · recruiting
- NCT06555757 — Utilising AI Analysis of Sounds To prEdict heaRt failurE decOmpensation · not yet recruiting
- NCT06427694 — Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study · recruiting
- NCT05866406 — The Effect of Time-Restricted Eating in Cardiometabolic Health · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07516496 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cambridge University Hospitals NHS Foundation Trust
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07516496.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing